Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-20263
Herzog, B A; Husmann, L; Valenta, I; Gaemperli, O; Siegrist, P T; Tay, FM; Burkhard, N; Wyss, C A; Kaufmann, P A (2009). Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. Journal of the American College of Cardiology, 54(2):150-156.
| PDF - Registered users only 1533Kb | ||
| Accepted Version 5Mb |
Abstract
OBJECTIVES: The goal of this study was to assess the predictive value of myocardial perfusion imaging with (13)N-ammonia positron emission tomography (PET) and coronary flow reserve (CFR) on long-term prognosis in patients with suspected myocardial ischemia. BACKGROUND: No prognostic data exist on the predictive value of CFR and (13)N-ammonia PET. METHODS: Perfusion and CFR were assessed in 256 patients using (13)N-ammonia PET, and follow-up was obtained in 245 (96%) patients. Sixteen early revascularized patients were excluded and 229 were assigned to normal versus abnormal perfusion or normal versus abnormal CFR (<2.0). Major adverse cardiac events (MACE) (cardiac death, nonfatal myocardial infarction, late revascularization, or hospitalization for cardiac reasons) were assessed using the Kaplan-Meier method. Cox proportional hazard regression was used to identify independent predictors for cardiac events. RESULTS: During follow-up (5.4 +/- 2.2 years), 78 patients had at least 1 cardiac event, including 29 cardiac deaths. Abnormal perfusion (n = 126) was associated with a higher incidence of MACE (p < 0.001) and cardiac death (p < 0.05). In patients with normal perfusion, abnormal CFR was independently associated with a higher annual event rate over 3 years compared with normal CFR for MACE (1.4% vs. 6.3%; p < 0.05) and cardiac death (0.5% vs. 3.1%; p < 0.05). In abnormal perfusion, CFR remained predictive throughout the 10-year follow-up (p < 0.001). CONCLUSIONS: Perfusion findings in (13)N-ammonia PET and CFR are strong outcome predictors. CFR allows further risk stratification, suggesting a "warranty" period of 3 years if normal CFR is associated with normal perfusion. Conversely, in patients with abnormal perfusion, an impaired CFR has added value for predicting adverse outcomes.
| Item Type: | Journal Article, refereed, original work |
|---|---|
| Communities & Collections: | 04 Faculty of Medicine > University Hospital Zurich > Clinic for Nuclear Medicine 04 Faculty of Medicine > Center for Integrative Human Physiology 04 Faculty of Medicine > University Hospital Zurich > Clinic for Cardiology |
| DDC: | 570 Life sciences; biology 610 Medicine & health |
| Language: | English |
| Date: | 07 July 2009 |
| Deposited On: | 18 Aug 2009 14:40 |
| Last Modified: | 23 Nov 2012 13:26 |
| Publisher: | Elsevier |
| ISSN: | 0735-1097 |
| Publisher DOI: | 10.1016/j.jacc.2009.02.069 |
| PubMed ID: | 19573732 |
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page